Cargando...
… What Do Payers Really Want To See?
Last fall’s launch of a lower-priced monoclonal antibody to treat colorectal cancer raised the question: Has the biotech industry opened a price war? Not necessarily. Even if it were so, payers would view it with skepticism – despite all the talk about the cost of biologic drugs. So when a lower-cos...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BioCommunications LLC
2007
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3555177/ https://ncbi.nlm.nih.gov/pubmed/23372510 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|